Epilepsy Genetics – A Practical Guide for Adult Neurologists

William Owen Pickrell\textsuperscript{1,2} and Andrew E. Fry\textsuperscript{3,4}

\textsuperscript{1}Department of Neurology, Morriston Hospital, Swansea Bay University Health Board, Swansea, Wales, UK
\textsuperscript{2}Swansea University Medical School, Swansea University, Swansea, Wales, UK
\textsuperscript{3}All Wales Medical Genomics Service, University Hospital of Wales, Heath Park, Cardiff, Wales, UK CF14 4XW
\textsuperscript{4}Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, Wales UK CF14 4XN, UK

Current Word Count (Limit 4000): Main text = 3028
Tables = 4
Figures =3
Boxes = 2
References = 78
Correspondence to Owen Pickrell, w.o.pickrell@swansea.ac.uk
Keywords
Epilepsy, genetics, adults.

Abstract
An understanding of epilepsy genetics is important for the adult neurologist as genetic diagnoses are of clinical benefit. In this review we describe the key features of different groups of genetic epilepsies. We describe the common genetic tests that are available and how to interpret them.

Key Points
- A genetic cause can be found for a proportion of adults with certain types of epilepsy and can be of clinical benefit.
- Epilepsy gene panels/whole exome sequencing and chromosomal microarrays are typically first line genetic tests with increasing use of genome sequencing.
- Genetic diagnoses can be missed in the paediatric clinic, be sceptical about historical aetiological diagnoses.
- Consider reviewing previous non-diagnostic genetic results in light of new evidence.
- Discussing genetic test results and cases within a multidisciplinary team including clinical geneticists and bioinformaticians is recommended.

Introduction
We have known about the link between epilepsy and genetics for a long time; Hippocrates wrote of epilepsy: “its origin is hereditary, like that of other diseases”. However, it wasn’t until 1995 that the first epilepsy gene was discovered. Since then, significant advances have been made in our understanding of epilepsy genetics. Although there is much we don’t understand, particularly in terms of the genetic architecture of the more common epilepsies, enough is now known that genetic diagnoses can be made and used to influence treatment decisions in the adult neurology clinic.

Most (but not all) single gene (monogenic) epilepsies will present in childhood and be diagnosed by our paediatric specialist colleagues. However, many of these children will transition to adult services where the genetic diagnosis may influence prognosis and treatment. The diagnosis might not have been made in the paediatric clinic. Precision therapies for certain epilepsies are available and will be an increasing part of clinical practice. It is important therefore that the adult neurologist has an understanding of epilepsy genetics. We do not offer a comprehensive review of epilepsy genetics here but describe key practical points for the adult neurologist seeing patients with epilepsy.

Taking a History
A family history is obviously important, but it is worth remembering that epilepsy is sometimes not fully disclosed in families, particularly in older generations. Speak with older family members if possible. Parents and grandparents can also help with recording the presence of febrile seizures in the patient and other family members which can be useful for the diagnosis of Genetic Epilepsy with Febrile Seizures plus (GEFS+).
febrile seizures are convulsive and occur in the context of fever between the ages of 6 months and 6 years. *Febrile seizures plus* (FS+) occur outside this age or may consist of seizures that occur with and without fever. Prolonged febrile seizures, particularly with a hemiclonic component, are associated with Dravet’s syndrome. Some monogenic epilepsies are due to *de novo* [footnote: Occurring due to a new mutation and not present in parents] or recessive mutations and there may be little or no family history in these situations.

The *age of onset* of different seizure types is particularly important and may give clues to a genetic diagnosis. For example early onset absence epilepsy (absences occurring in a child less than four years old) is associated with *SLC2A1* mutations, most seizures start before the age of 20 in autosomal dominant nocturnal frontal lobe epilepsy, and age of onset helps with diagnosing particular developmental and epileptic encephalopathies (DEEs) (table 1).

*Birth details* are traditionally part of the epilepsy history given that perinatal events can cause epilepsy. However, changes in neonatal care have, for the most part, improved outcomes, and having a premature or a traumatic birth or a previous label of cerebral palsy might not exclude a genetic cause for epilepsy. In a recent study, 58% of adults with epilepsy and intellectual disability, who had previously been thought to have a known historic cause for their epilepsy such as perinatal trauma, were found to have a genetic diagnosis. Infants with neurological abnormalities may also be more likely to have difficult deliveries e.g. due to hypotonia.

**Specific scenarios**

**Developmental and Epileptic encephalopathies.**

DEEs are an overlapping group of syndromes, normally presenting in childhood, with severe epilepsy and associated cognitive and behavioural impairment. The seizures themselves may be the key driver to the cognitive impairment (epileptic encephalopathy) or play a less prominent role (developmental encephalopathy) but most often there is a significant overlap.

The vast majority of DEEs present in childhood but a significant proportion of patients transition to, or present in the adult clinic. In the adult neurology clinic we have an opportunity to make a genetic diagnosis in previously “unsolved” DEEs or DEEs falsely ascribed to symptomatic causes such as mild perinatal trauma. We also need to be aware of specific treatment options for some DEEs.

Although structural and metabolic brain problems can cause DEEs, they are mostly genetic in origin. Significant inroads have been made in understanding the underlying genetics of these disorders which are often associated with *de novo* mutations. There are over one hundred genes associated with DEEs.

Epilepsy gene panels or whole exome/genome sequencing are standard diagnostic clinical tests for patients with DEEs and should be requested if not already done so. In some ways these tests reduce the need to remember the large number of genes associated with DEEs. Be familiar with some of the more important DEEs though (table 1) as having a clear epilepsy phenotype can help interpret genetic results. However, many individuals with a
DEE do not have a distinct phenotype and genetic testing should still be considered in these cases.
### Dravet syndrome

**Age at onset:** 1\textsuperscript{st} year of life, typically around 6 months

Seizures associated with fever (especially hemiclonic, or status epilepticus) common at onset. Multiple seizure types in the first year: hemiclonic, myoclonic and focal seizures with status epilepticus. Development delay usually apparent in second year and usually moderate to severe intellectual impairment. Seizures (and fever sensitivity) persist throughout life but frequency may decrease. Higher risk of sudden unexplained death in epilepsy (SUDEP). Motor problems (“crouching” gait) and decline in mobility, behavioural problems and swallowing difficulties feature in adulthood. Sodium channel anti-seizure medications can make seizures worse. Treatment options include fenfluramine, cannibidol and ketogenic diet.

### Early infantile epileptic encephalopathy

**Age at onset:** 0–3 months

Frequent intractable seizures, tonic seizures. Consider early myoclonic encephalopathy if myoclonic seizures predominate. Structural brain aetiology most common. Also, metabolic as well as genetic causes. Can evolve to West or Lennox-Gastaut Syndrome. Normally severe developmental delay. Abnormal EEG with burst suppression can evolve to hypsarrhythmia.

### Epilepsy of infancy with migrating focal seizures

**Age at onset:** 1\textsuperscript{st} year of life, typically 0–6 months

Rare and severe with focal seizures migrating between hemispheres. Most have severe developmental problems after onset of seizures. EEG can be normal initially, slowing with time, ictal changes correlate with seizures.

### West syndrome

**Age at onset:** 1\textsuperscript{st} year of life, typically around 6 months

Infantile spasms at onset with EEG hypsarrhythmia. Structural (tuberous sclerosis) and metabolic causes as well as genetic causes. Corticosteroids, vigabatrin and the ketogenic diet can be useful. Can evolve to Lennox-Gastaut syndrome.

### Epileptic encephalopathy with continuous spike-and-wave during sleep

**Age at onset:** Childhood onset, typically 4–5 years.

Progressive cognitive decline is prominent and is associated with characteristic EEG abnormality of continuous slow spike and wave in slow sleep. Seizures can remit but cognitive impairment can persist. A spectrum including Landau-Kleffner syndrome (milder phenotype with prominent aphasia).

### “Metabolic” DEEs

Rare but potentially treatable genetic metabolic problems which can present as a DEE include: guanidinoacetate methyltransferase (GAMT) deficiency – DEE phenotype, low serum creatinine can be a clue, check plasma and urine creatine, creatinine and guanidinoacetate. MR spectroscopy can be diagnostic. Oral creatine supplementation and dietary manipulation can cause dramatic improvements. Pyridoxine dependent epilepsy (PDE) is typically neonatal onset with drug resistant epilepsy and a DEE phenotype that responds to high doses of pyridoxine. Elevated plasma and urinary levels of alpha-aminoacidic semialdehyde.

---

Table 1: Important developmental and epileptic encephalopathies (DEEs).

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Age at onset</th>
<th>Clinical Features / Pointers</th>
<th>Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dravet syndrome</td>
<td>1\textsuperscript{st} year of life, typically around 6 months</td>
<td>Seizures associated with fever (especially hemiclonic, or status epilepticus) common at onset. Multiple seizure types in the first year: hemiclonic, myoclonic and focal seizures with status epilepticus. Development delay usually apparent in second year and usually moderate to severe intellectual impairment. Seizures (and fever sensitivity) persist throughout life but frequency may decrease. Higher risk of sudden unexplained death in epilepsy (SUDEP). Motor problems (“crouching” gait) and decline in mobility, behavioural problems and swallowing difficulties feature in adulthood. Sodium channel anti-seizure medications can make seizures worse. Treatment options include fenfluramine, cannibidol and ketogenic diet.</td>
<td>&gt;80% have pathogenic SCN1A variants. Other genes associated with similar phenotype include GABRA1, GABRG2, HCN1, KCNA2, SCN1B.</td>
</tr>
<tr>
<td>Early infantile epileptic encephalopathy</td>
<td>0–3 months</td>
<td>Frequent intractable seizures, tonic seizures. Consider early myoclonic encephalopathy if myoclonic seizures predominate. Structural brain aetiology most common. Also, metabolic as well as genetic causes. Can evolve to West or Lennox-Gastaut Syndrome. Normally severe developmental delay. Abnormal EEG with burst suppression can evolve to hypsarrhythmia.</td>
<td>STXBP1 (most common maybe 10%) others include SCN2A, STXBP1, and KCNQ2.</td>
</tr>
<tr>
<td>Epilepsy of infancy with migrating focal seizures</td>
<td>1\textsuperscript{st} year of life, typically 0–6 months</td>
<td>Rare and severe with focal seizures migrating between hemispheres. Most have severe developmental problems after onset of seizures. EEG can be normal initially, slowing with time, ictal changes correlate with seizures.</td>
<td>Genes include KCNT1 (30%), SCN2A, SCN1A, PLCB1, TBC1D24 and CHD2.</td>
</tr>
<tr>
<td>West syndrome</td>
<td>1\textsuperscript{st} year of life, typically around 6 months</td>
<td>Infantile spasms at onset with EEG hypsarrhythmia. Structural (tuberous sclerosis) and metabolic causes as well as genetic causes. Corticosteroids, vigabatrin and the ketogenic diet can be useful. Can evolve to Lennox-Gastaut syndrome.</td>
<td>Genes include CDKL5, ARX, SPTAN1 and STXBP1</td>
</tr>
<tr>
<td>Epileptic encephalopathy with continuous spike-and-wave during sleep</td>
<td>Childhood onset, typically 4–5 years.</td>
<td>Progressive cognitive decline is prominent and is associated with characteristic EEG abnormality of continuous slow spike and wave in slow sleep. Seizures can remit but cognitive impairment can persist. A spectrum including Landau-Kleffner syndrome (milder phenotype with prominent aphasia)</td>
<td>GRIN2A</td>
</tr>
<tr>
<td>“Metabolic” DEEs</td>
<td></td>
<td>Rare but potentially treatable genetic metabolic problems which can present as a DEE include: guanidinoacetate methyltransferase (GAMT) deficiency – DEE phenotype, low serum creatinine can be a clue, check plasma and urine creatine, creatinine and guanidinoacetate. MR spectroscopy can be diagnostic. Oral creatine supplementation and dietary manipulation can cause dramatic improvements. Pyridoxine dependent epilepsy (PDE) is typically neonatal onset with drug resistant epilepsy and a DEE phenotype that responds to high doses of pyridoxine. Elevated plasma and urinary levels of alpha-aminoacidic semialdehyde.</td>
<td>GAMT (GAMT deficiency) – recessive ALDH7A1 (PDE) – recessive</td>
</tr>
</tbody>
</table>
Specific Genetic Epilepsy Phenotypes

Some epilepsies have well described genetic causes. For example, familial epilepsy syndromes or epilepsies due to mitochondrial disease (table 2)—request genetic testing in these cases.
<table>
<thead>
<tr>
<th>Gene/Syndrome</th>
<th>Clinical presentation/clues</th>
<th>Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic epilepsy with febrile seizures plus (GEFS+)</td>
<td>A wide spectrum of epilepsies within the family consisting predominately of febrile seizures but also febrile seizures plus**, generalised (absence, myoclonic, atonic) and focal seizures. A GEFS+ family has at least two individuals with GEFS+ phenotypes, including at least one with febrile seizures or febrile seizures plus (figure 1). GEFS+ families may have individuals with developmental or epileptic encephalopathies, particularly Dravet syndrome or Myoclonic-astatic epilepsy.</td>
<td>SCN1A (19%), GABRG2 (9%), SCN1B (8%)</td>
</tr>
<tr>
<td>Glucose transporter 1 deficiency syndrome (GLUT1)</td>
<td>Variants in SLC2A1 which encodes a brain glucose transporter can produce a spectrum of phenotypes including epileptic encephalopathies and milder epilepsies with or without intellectual disability. Can also cause early onset absence epilepsy (onset &lt;4 years) and/or paroxysmal exercise induced dyskinesia (limb movements including dystonia and chorea after exercise). Responds well to the ketogenic diet.</td>
<td>SLC2A1</td>
</tr>
<tr>
<td>Autosomal dominant sleep-related hypermotor epilepsy (ADSHE)*</td>
<td>Seizures from sleep usually starting in childhood and persisting into adulthood. Brief tonic or hypermotor seizures occurring in clusters. Awake seizures are rare. Mostly drug responsive, particularly to carbamazepine. Sometimes more severe with drug resistance and intellectual disability/psychiatric comorbidities, KCNT1 variants associated with a more severe phenotype.</td>
<td>CHRNA4, CHRNB2, CHRNA2 (nicotinic AChR subunit genes) and DEPDC5 KCNT1.</td>
</tr>
<tr>
<td>Autosomal dominant epilepsy with auditory features (ADEAF)</td>
<td>Seizures with auditory features typically starting in adolescence. Auditory auras, commonly sounds such as ringing or buzzing, sometimes receptive aphasia and auditory hallucinations. Focal and focal to bilateral convulsive seizures. Seizures can be sometimes triggered by sounds. Relatively drug responsive.</td>
<td>LGII (30–50% of familial cases, 2% of sporadic cases). Also DEPDC5, RELN.</td>
</tr>
<tr>
<td>Familial focal epilepsy with variable foci (FFEVF)</td>
<td>Focal epilepsy in multiple family members with different seizure foci in different family individuals (seizure focus remaining constant within the individual). E.g. temporal lobe epilepsy in the proband, frontal lobe epilepsy in father, occipital lobe epilepsy in grandfather. Variety in epilepsy onset and severity but mostly drug responsive, sometime psychiatric comorbidity. Can occur in families with fewer affected individuals. DEPDC5 is part of the mammalian target of rapamycin pathway raising possible treatment options.</td>
<td>DEPDC5 (around 80%).</td>
</tr>
<tr>
<td>Ring chromosome 20 syndrome</td>
<td>Rare. Focal onset, drug resistant, seizures with frontal lobe semiology starting dramatically in childhood, typically around the age of 7. Hyperkinetic seizures during sleep as well as focal seizures with altered awareness and non-convulsive status epilepticus. Onset of seizures can be preceded by marked nocturnal hallucinations and behavioural/developmental disturbance after the onset of seizures is common.</td>
<td>Ring formation on chromosome 20 – check karyotype. (figure 2)</td>
</tr>
<tr>
<td>Mitochondrial disease</td>
<td>Clues include deafness, diabetes and short stature as well as occipital onset seizures and non-convulsive status epilepticus. Myoclonic epilepsy with ragged red fibres (MERRF) can present as a progressive myoclonic epilepsy with cognitive change, ataxia, short stature, and multiple lipomas. Mitochondrial encephalopathy with lactic acidosis and Stroke-like episodes (MELAS) can present in adulthood. Seizures are a key features of the stroke-like episodes and headache and vomiting can also features. POLG-related epilepsies can be</td>
<td>POLG and mitochondrial genes m.8344A&gt;G (90% of MERRF) MELAS: m.3243A&gt;G; m.3271T&gt;C</td>
</tr>
</tbody>
</table>

**Note:** * indicates a gene and syndrome.
severe (Alpers-Huttenlocher Syndrome) and present with convulsive status epilepticus and epilepsy partialis continua in childhood and adolescence as well as cognitive changes and hepatopathy. Avoid sodium valproate in POLG disease.\textsuperscript{32}

| Table 2 Clinical features of important genetic epilepsies and associated genetic conditions in the adult clinic. *Previously known as autosomal dominant nocturnal frontal lobe epilepsy. **Febrile seizures plus are febrile seizures occurring outside the normal age range for febrile seizures (6 months to 6 years) or afebrile seizures occurring concurrently with febrile seizures. AChR = Acetylcholine receptor. §Previously called autosomal dominant partial/lateral temporal epilepsy with auditory features. |
Progressive Myoclonic Epilepsies

The progressive myoclonic epilepsies (PME) are a rare, heterogeneous group of disorders characterized by predominantly progressive myoclonic seizures and progressive cognitive decline and ataxia (table 3). Of note is that cognition is largely preserved in Unverricht-Lundborg disease. PMEs predominantly present in childhood or early adolescence and are mostly autosomal recessive. Consider PME in a case of juvenile myoclonic epilepsy with progressive (particularly action) myoclonus, additional features such as ataxia or cognitive decline and a family history. It is now possible to get a genetic diagnosis for at least 70% of PMEs.
**Unverricht-Lundborg disease (ULD)**


**Genetics**

CSTB (dodecamer nucleotide repeats)

**Neuronal ceroid lipofuscinosis (NCL)**

Group of neurodegenerative lysosomal storage disorders. Common cause of childhood dementia. Prominent cognitive decline and visual failure, also cerebellar atrophy myoclonus and other seizures. Genetically heterogeneous, currently at least 14 genes, age at onset useful to classify. Other diagnostic tests e.g. skin biopsy can be useful.

**Genetics**

Loci: CLN1-14

Genes: PPT1, TPP1, CLN3, DNAJC5, CLN5, CLN6, MFSD8, CLN8, CTSD, ATP13A2, CTSF, KCTD7

**Lafora disease (LD)**

Adolescent onset in otherwise normal individuals. Headaches, myoclonus, occipital seizures, visual hallucinations. Biopsy can reveal Lafora bodies (polyglucosan inclusions). Progressive dementia and death usually 10 years after onset.

**Genetics**

EPM2A, NHLRC1, PRDM8

**Others**

*Myoclonic Epilepsy with Ragged Red Fibres (MERRF)* – see table 2. *Sialidosis* is a lysosomal storage disorder with ‘cherry red spots’ seen on fundoscopy as well as visual decline, ataxia and dysmorphia (sialidosis type 2). *Spinal muscular atrophy associated with progressive myoclonus epilepsy (SMA-PME)* is caused by acid ceramidase deficiency and has typically distal lower motor neurone weakness.

**Genetics**

MERRF (mitochondrial)

Sialidosis: NEU1,

SMA-PME: ASAH1

---

**Table 3 The progressive myoclonic epilepsies (PME).**
Malformations of cortical development

Malformations of cortical development (MCD) are neurodevelopmental disorders caused by abnormal formation of the cerebral cortex. They are diverse in their aetiology and presentation but represent a common cause of intractable epilepsy.\(^4^3\) In the adult epilepsy clinic MCDs are typically discovered with an abnormal MRI of the brain. Table 4 lists some of the most common MCDs.

Many MCDs have genetic causes and recommended genetic investigations include a chromosomal microarray and an MCD gene panel.\(^4^3\) However, some MCDs are due to mosaic mutations (e.g. focal cortical dysplasia and hemimegalencephaly). Causative mosaic mutations may only be present in the brain and either absent or rare in other body tissues. Mosaic mutations can therefore be missed by standard tests on blood-derived DNA. Detection may require testing of alternative tissue samples (saliva, skin or brain material) and/or targeted testing (ultra-deep resequencing).

Other Structural Brain Abnormalities

Tuberous sclerosis complex is characterised by multiple benign tumours in the skin, brain and other organ systems with a variety of clinical features and presentations. Cutaneous manifestations (hypopigmented macules, angiofibromas, shagreen patches and forehead fibrous plaques) and neuropsychiatric problems occur in >90% of patients.\(^4^4\)\(^4^5\) Epilepsy occurs in around 80% of cases, tends to be early onset and can be severe.\(^4^5\) De-novo (80%) and familial (autosomal dominant) mutations in \(TSC1\) and \(TSC2\) are found in more than 90% of tuberous sclerosis cases and cause an overactivation of the mTOR pathway.\(^4^5\)\(^4^6\) As well as anti-seizure medications, including cannibidol and vigabatrin, treatment options include mTOR inhibitors such as everolimus, the ketogenic diet and surgery.\(^4^5\)

Cerebral cavernous malformations or cavernomas are low flow vascular malformations that can cause epilepsy as well as being relatively common incidental MRI findings.\(^4^7\) Around 20% of patients have a familial, autosomal form of the disease and tend to have multiple cavernous malformations and pathogenic variants in one of three main genes: \(CCM1\) (\(KRIT1\)), \(CCM2\) and \(CCM3\) (\(PDC10\)).\(^4^8\) Treatment of epilepsy associated with cavernous malformations normally involves anti-seizure medications although surgery can be an option.\(^4^8\)

Other genetic structural brain abnormalities that may cause epilepsy include leukoencephalopathies and neurofibromatosis.\(^4^9\)\(^5^0\)
<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Description</th>
<th>Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Periventricular nodular heterotopia (PVNH)</td>
<td>Grey matter along the ventricular walls unilaterally or bilaterally. Can occur as part of another disorder. Can be caused by FLNA mutations (X-linked) which increase risk of systemic complications including heart, lung and GI disease. FLNA disease mostly affects females as usually lethal in males.</td>
<td>Numerous copy number variants and single gene mutations (including FLNA)</td>
</tr>
<tr>
<td>Polymicrogyria</td>
<td>Overfolding and abnormal cortical lamination. MRI: apparent cortical thickening with irregular cortical surface and ‘stippled’ grey-white junction. Genetic and congenital causes. Congenital CMV infection accounts for around 30% of cases (suspect if additional microcephaly, congenital hearing loss, intracranial calcification). Can be associated with peroxisomal disorders (additional leukoencephalopathy) check plasma very long chain fatty acids.</td>
<td>Copy number variants including 22q11.2 and 1p36 deletions and many single gene mutations including GRIN1, WDR62, PIK3CA and PIK3R2</td>
</tr>
<tr>
<td>Lissencephaly spectrum</td>
<td>“smooth brain”, absent or reduced gyri. Spectrum encompasses agryria, pachgyria and subcortical band heterotopia. Mostly genetic causes, MRI findings/patterns can strongly predict genotype.</td>
<td>Include LIS1, DCX, TUBG1, TUBA1A, ARX</td>
</tr>
<tr>
<td>Subcortical band heterotropia</td>
<td>Part of the lissencephaly spectrum. A band of grey matter separated from the cortex and lateral ventricles by zones of grey matter.</td>
<td>LIS1 (PAFAH1B1), DCX</td>
</tr>
<tr>
<td>Subcortical heterotropia (SUBH)</td>
<td>Heterotopic grey matter within the white matter between cortex and lateral ventricles. Less common to find genetic cause.</td>
<td>Mostly recessive, include GPSM2, EML1 TUBB, KATNB1 or CENPJ</td>
</tr>
<tr>
<td>Tubulinopathies</td>
<td>Microtubules are important for neurodevelopment and mutations in tubulin genes can cause a range of MCDs including pachgyria, polymicrogyria and microlissencphaly. Additional features include dysmorphic basal ganglia, “hooked” frontal horns in the ventricles, agenesia of the corpus callosum and cerebellar and brainstem hypoplasia. Each tubulin gene is associated with a predominant phenotype.</td>
<td>Include TUBA1A, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB and TUBG1</td>
</tr>
<tr>
<td>Focal cortical dysplasia (FCD)</td>
<td>Focal irregularities of cortical morphology and thickness. Indistinct grey-white boundary. Can be subtle and occur as part of tuberous sclerosis. Overlap with Familial focal epilepsy with variable foci (FFEVF) (table 2)—consider if familial epilepsy.</td>
<td>mTOR pathway genes including TSC1, TSC2, MTOR; GATOR1 complex genes including DEPDC5, NPRL2 NPRL3.</td>
</tr>
</tbody>
</table>

Table 4 – Some Malformations of cortical development (MCD) that can cause epilepsy.
‘Common’ Epilepsies

Most people with epilepsy in clinic will have generalised or non-lesional focal epilepsy [footnote: No obvious acquired cause (e.g. stroke, cerebral infection, traumatic brain injury) for the epilepsy and a normal MRI brain or a MRI brain without a lesion to explain the epilepsy], without an underlying cause, family history or suggestion of a known genetic phenotype. Genetics makes a significant contribution to the aetiology of these common, idiopathic epilepsies with the risk of developing epilepsy increased two to four times in first-degree relatives and increased concordance in monozygotic twins.\(^5\)\(^6\)\(^7\)

It is unlikely that these epilepsies are caused by a single genetic problem. One study found heterozygous intestinal-cell kinase variants in 7% of individuals with Juvenile Myoclonic Epilepsy, but this finding could not be replicated in a large independent cohort.\(^5\)\(^8\)\(^9\)

We now know that the combined effect of common genetic variants, rare genetic variants and copy number variants contribute towards the genetic cause of common epilepsies.\(^2\)\(^2\)\(^6\)\(^0\)\(^6\)\(^1\)\(^2\)\(^3\)\(^4\)\(^5\)\(^6\)\(^7\)\(^8\)\(^9\)\(^0\)

Other genetic mechanisms that are likely to play a role include modifier genes, nucleotide repeats, and epigenetic factors.\(^5\)\(^2\)\(^2\)\(^6\)

At present we would not routinely recommend genetic tests for common, idiopathic generalised or drug-responsive focal epilepsies without additional features (see box 1). This could change in the future, for example polygenic risk scores may provide information on the prognosis and treatment options available for idiopathic epilepsies.\(^5\)

Treatment and prognosis

Obtaining a genetic diagnosis can inform treatment options.\(^6\)\(^4\) For example sodium channel blocking drugs should be avoided in Dravet syndrome caused by SCN1A loss of function mutations, the ketogenic diet may improve outcomes for people with SLC2A1 mutations and sodium valproate can cause severe hepatotoxicity in POLG deficiency.\(^6\)\(^4\) Genetic treatments, for example anti-sense oligonucleotide therapies, have been used experimentally for epilepsy and hold significant promise for the future.\(^6\)\(^5\)

Human Leucocyte Antigen (HLA) genotype can influence the risk of severe adverse drug reactions and HLA genotyping can be considered before starting carbamazepine treatment (HLA-B*1502 for certain Asian ethnicities and HLA-A*3101 for Japanese, Korean and European ethnicity).\(^6\)\(^6\)\(^6\) There are no other clinical pharmacogenetic tests at present despite the likelihood that genetics influences treatment response.

Recent studies have shown higher schizophrenia polygenic risk scores in people with epilepsy with post-ictal psychosis and levetiracetam induced psychosis when compared to those without.\(^6\)\(^8\)\(^6\)\(^9\) This raises the possibility that genetic testing may help predict prognosis and outcomes in future, although none are clinically available at present.\(^7\)\(^0\)
Genetic Testing

When should I request a genetic test in epilepsy clinic?

The threshold for requesting an epilepsy genetic test is continuing to fall. It may be in the near future that almost all people with epilepsy will have a genetic test. However currently we would recommend prioritising genetic testing for cases where results are most likely to have the highest yield and influence clinical management (box 1).\(^{71}\)

<table>
<thead>
<tr>
<th>Developmental and Epileptic encephalopathies (DEEs) (table 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilepsy with intellectual disability and/or other neurodevelopmental disorder</td>
</tr>
<tr>
<td>Individual and or family phenotype suggestive of a known genetic cause (table 2)</td>
</tr>
<tr>
<td>Features suggestive of mitochondrial disease (table 2)</td>
</tr>
<tr>
<td>Progressive myoclonic epilepsies (table 3)</td>
</tr>
<tr>
<td>Malformations of cortical development (table 4) or other genetic structural abnormality</td>
</tr>
<tr>
<td>Early onset (&lt;3 years)</td>
</tr>
<tr>
<td>Drug resistant epilepsy of unknown aetiology</td>
</tr>
</tbody>
</table>

*Box 1 Clinical scenarios where genetic testing is indicated*

Advantages and disadvantages to genetic testing

Obtaining a genetic diagnosis can have clear clinical benefits. These include: selecting specific treatment options and avoiding contraindicated treatments, informing prognosis, enabling pre-conception planning and genetic counselling, preventing unnecessary investigation, identifying groups of patients for clinical trials, providing an explanation, and *ending the diagnostic odyssey*.\(^{72,73}\)

There are also disadvantages. It is important to consider the broader implications of requesting a genetic test, discussing these with the patient and/or family as part of the consent process. For example, test results may not give an answer, have implications for other family members, give uncertain results (variants of uncertain significance), and provide additional unexpected findings (particularly with whole exome and genome sequencing). Unexpected findings can include risk factors for health problems (e.g. heart disease or cancer) and uncover sensitive issues such as non-paternity in families.\(^{74}\)

What genetic test should I do?

**Chromosomal microarrays**

Molecular methods have replaced routine karyotyping, where chromosomes are stained and visualised by microscope, to detect structural genomic variants. These chromosomal microarrays (or simply ‘arrays’) complement gene panels and exomes because they are sensitive to medium- and large-scale deletions and duplications [also known as ‘copy number variants’ (CNVs)] which are often missed by sequencing-based tests.
The main array methods used are comparative genomic hybridisation (CGH) or Single Nucleotide Polymorphism (SNP) based platforms. SNP arrays have the advantage of being sensitive to uniparental disomy [footnote: inheriting two copies of the same chromosome from one parent] which can be relevant to conditions such as Angelman syndrome and Prader-Willi syndrome.

Chromosomal microarrays are now the standard tests used to detect CNVs from around a few hundred kilobases in size (figure 2). CNVs are part of normal genetic variation (perhaps accounting for 5–10% of the human genome).\(^75\) CNVs can cause disease though and several specific CNVs are associated with epilepsy, these include 1q21.1, 15q13.3, 15q11.2, 16p11.2 and 16p13.11.\(^76\)\(^77\)

Chromosomal microarrays are insensitive to balanced rearrangements such as inversions, translocations and ring chromosomes. For example, karyotyping should be requested if ring chromosome 20 \([\text{r}(20)]\) syndrome is suspected (see table 2 and figure 3). \(\text{R}(20)\) is a rare condition where the ends of chromosome 20 fuse to form a ring structure replacing the normal chromosome 20 (figure 3).\(^31\) \(\text{R}(20)\) is frequently mosaic [footnote: Occurring in only a proportion of cells] and so a repeat karyotype test or visualisation of more cells should be considered, after discussion with the genetics lab, if there is a strong clinical suspicion.\(^31\)

A chromosomal microarray should be considered in an adult with unexplained epilepsy particularly if there is comorbid intellectual disability, dysmorphism, autism or schizophrenia or a family history of these conditions. The overall diagnostic yield of arrays in selected populations can be around 10%.\(^73\)

**Epilepsy Gene Panels**

Epilepsy gene panels, together with whole exome and genome sequencing, are perhaps the most common and useful genetic tests in the adult epilepsy clinic at present. Multiple (hundreds) of genes can be tested in one request.

The overall yield of an epilepsy gene panel may be around 20% but will vary with certain phenotypes and the number of genes included on the panel.\(^73\) The genes that are screened on gene panels will change with time, vary regionally and nationally, and tend to be grouped into broad phenotypes e.g. developmental and epileptic encephalopathies, progressive myoclonic epilepsies or malformations of cortical development and so it is worth checking with your genetics lab. For example, almost all genes mentioned in this paper can be found in the Genomics England \(\text{R87 cerebral malformations or R59 Early onset or syndromic epilepsy panels.}\(^78\)

**Whole Exome and Whole Genome Sequencing**

These are now regularly being used clinically, often with input from a local genetics service. Genome sequencing, particularly with longer read technology, can be used to detect copy number variants and may replace the current separate microarray and gene panel approach soon as a “one-stop shop” for genetic testing.\(^79\)\(^80\)\(^81\)

Many testing centres will use virtual gene panels where sets of genes are selected for analysis from whole exome or genome sequencing results. This has the advantage of reducing the variant interpretation workload associated with whole exome and genome sequencing, being able to reanalyse different genes in future and maintaining diagnostic yield.\(^82\)
Additional genetic analysis

Chromosomal microarrays and current sequencing-based tests are limited in their ability to detect certain types of genetic variation. Additional targeted testing needs to be considered if these are suspected. Examples include mosaic genetic changes (see above), mitochondrial mutations, repeat expansion disorders and imprinting disorders (and promotor and intronic variants for exome sequencing).

Consider mitochondrial genetic testing if there are features of mitochondrial disease (table 1). Mitochondrial tests range from targeted testing for point mutations (e.g. MELAS, NERFF, NARP), to assays for large deletions and duplications, to whole mitochondrial genome sequencing. Variable tissue distribution may mean that variants are undetectable in blood requiring testing of muscle or urine sediment. It should be remembered that mitochondrial disorders are often caused by defects in genes encoded in the nuclear genome e.g. POLG.

Some epilepsies and disorders associated with epilepsy are cause by nucleotide repeat disorders. These include Unverricht-Lundborg disease (table 3) and benign adult familial myoclonic epilepsy, a rare autosomal dominant condition with cortical tremor and myoclonus and infrequent generalised tonic clonic seizures. Other repeat expansion disorders associated with epilepsy include Fragile X syndrome (also associated with intellectual disability and autism) and Huntington disease. Targeted PCR or Southern blotting-based techniques are required to detect these.

Angelman syndrome and Prader-Willi syndrome are examples of disorders than can be caused by abnormal methylation patterns on chromosome 15 (in addition to large chromosomal deletions and uniparental disomy as discussed above). Targeted methylation-sensitive PCR can detect methylation abnormalities as well as uniparental disomy.

How do I interpret genetic test results?

As gene panel, exome sequencing and genome sequencing are becoming more widespread we are getting more confident in interpreting their results. Please also see some excellent articles from this journal.

Clinical genomic laboratories employ international guidelines such as those from the American College of Medical Genetics for variant interpretation. These attempt to bring objectivity and consistency to the challenge of variant interpretation. Currently American College of Medical Genetics guidelines use features such as evolutionary conservation, phenotype match, computer predictions, population genetic data and family segregation to classify variants as either: pathogenic, likely pathogenic, uncertain significance, likely benign or benign.

If the test reports a variant as pathogenic, with an established phenotype matching your patient’s, then you probably have the answer. Like any other clinical test there is the chance of false positive and false negative results however and sometimes it can be difficult to interpret the clinical significance of some results. Factors that you should consider when interpreting your results are shown in box 2. Remember that it is possible for a patient to have more than one genetic diagnosis. It is important to consider whether enough of a genetic explanation has been found (e.g., a 1q21.1 deletion detected by chromosomal microarray is a risk factor for epilepsy but would not be sufficient to explain a severe DEE).
Is there a zygosity mismatch between previously published results and your result? i.e. previously published genotypes are homozygous but the results are heterozygous.

Do the phenotypes match (although phenotypic heterogeneity is common in epilepsy)?

Is this a previously published or described variant?

The quality of published evidence of the pathogenicity of the variant.

Is this a variant that is present in the general population? (in this case it is less likely to explain a rare epilepsy)

Does the variant segregate in the family? i.e. affected family members carry the variant and unaffected family members do not carry the variant.

**Box 2 Factors to consider when deciding on the clinical significance of genetic results**

In South Wales we have established a quarterly epilepsy genetics multidisciplinary team meeting, attended by clinical geneticists, genetic laboratory scientists, paediatric neurologists, specialist nurses as well as neurology trainees and adult neurologists. We would advise discussing patients and test results within the genetic multidisciplinary team to aid clinical decision making and the interpretation of genetic test results. Without access to a formal genetics meeting, we would advise discussing genetic test results and requests with clinical and laboratory genetics staff and colleagues if there is any doubt.

In cases without a definite genetic diagnosis, it is worth considering research participation to look for new genetic causes, periodic reanalysis of genomic data or retesting with newer testing techniques.  

**Further Reading**

[www.epilepsydiagnosis.org](http://www.epilepsydiagnosis.org)  *Useful website with definitions of epilepsy syndromes including genes.*

[www.epilepsygenetics.net](http://www.epilepsygenetics.net) Beyond the ion channel the International League Against Epilepsy (ILAE) genetics commission Blog. *Written by Dr Ingo Helbig and contains a host of very readable blogs about epilepsy genetics and related topics. Subscribe for an email update!*  


**Acknowledgements**

We would like to thank Dr Jana Jezkova, Clinical Scientist and Postdoctoral Fellow at Cardiff University for her help with the figures.
Conflict of Interests

The authors confirm that they have no relevant conflict of interests to declare
Figure 1 An example of a family with Genetic Epilepsy with Febrile Seizures Plus (GEFS+) – see table 2. Squares are male, circles are female. Red quadrants represent febrile seizures. Red halves represent febrile seizures plus (febrile seizures occurring outside the ages of 6 months and 6 years or afebrile seizures occurring concurrently with febrile seizures). Complete grey shading represents epilepsy.
Figure 2 Output from a single nucleotide polymorphism (SNP) microarray a common way to look for copy number variants (CNVs). In this case there was a CNV, a deletion, on the short arm of chromosome 4. The lower box (B) is a scaled plot around the deletion and the yellow box highlights the deletion. There is a lower log R ratio in the yellow area representative of less sample DNA (a deletion). DNA duplications have areas of higher log R. The log R is a measure of signal intensity and correlates with the amount of DNA present.
Figure 3 Karyotype showing a ring chromosome 20 (arrow). Ring chromosome 20 syndrome is a rare cause of epilepsy (table 2)
References


45. Curatolo P, Specchio N, Aronica E. Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. *The Lancet Neurology* 2022;21(9):843-56. doi: [https://doi.org/10.1016/S1474-4422(22)00213-7](https://doi.org/10.1016/S1474-4422(22)00213-7)


64. Sisodiya SM. Precision medicine and therapies of the future. Epilepsia 2021;62(S2):S90-S105. doi: https://doi.org/10.1111/epi.16539


